Himadri Speciality Chemical — a carbon master betting on batteries
Himadri Speciality Chemical Ltd
Snapshot
Himadri turns coal tar — a black, sticky leftover from making steel — into useful, high-value carbon products. It is India’s No. 1 coal-tar pitch maker (the glue that holds aluminium smelters running), a top-5 global speciality carbon black player, and now it is spending big to become the first company outside China to make LFP battery cathode material at commercial scale. Market cap ₹33,857 cr, price ₹671 (52-week range ₹418–₹718), P/E 45.2, P/B 7.2×, RoE 17.8%, RoCE 22.1%.
What kind of animal is this? A Good business that has fought its way up to nearly Great on its core, with a large, unproven, capital-hungry option (batteries) bolted on top. As of 2026-06-20, from screener snapshot.
The verdict in two boxes — the business first, the price second
Keep them apart on purpose. Box 1 would read the same if the share price doubled or halved tomorrow. Box 2 is today’s weather.
Box 1 — The business (durable):
| Lens | Result |
|---|---|
| Business-quality score | 17.5 / 23 (Quality 9/12 · Growth 5/6 · Longevity 3.5/5) |
| Buffett rubric | 6.5 / 10 PASS |
| Business bucket | Good, edging toward Great on the core |
| Wealth-creator type | Enduring (core) · was Volatile, now turning Consistent |
| Economic Profit | +₹273 cr (RoE 17.8% − CoE 12% on ₹4,706 cr net worth) — creating value |
A Good business — capital-hungry but now earning well above its cost of money — that has become a genuine wealth creator on its core, independent of what it costs today. The battery bet could make it Great or could be a costly detour; that part is not yet proven.
Box 2 — The price today (a current phenomenon):
| Reading | Result |
|---|---|
| CMP | ₹671 (as of 2026-06-20) |
| Price pillar | 0.5 / 2 (PEG ~1.7× on guided growth · 5-yr payback ~4.3×) |
| Margin-of-safety band | ₹390–₹520 (P/E ~26–35× on FY26 EPS of ₹14.89) |
| Mr. Market’s mood now | Greedy — paying up front for a battery future that is still pre-profit |
| CMP vs the band | Demanding — roughly 30–70% above the band |
Today the market is pricing it rich — a mood driven by excitement about lithium-battery materials and “the only non-Chinese LFP at scale,” which can cool quickly while the carbon business above keeps quietly compounding.
In plain English
Picture a steel mill. When it bakes coal into coke, it spits out a gooey black tar nobody wants. Himadri’s whole life’s work is buying that tar cheap and refining it into things the world badly needs: coal-tar pitch (the binder that keeps aluminium smelters from freezing solid — once a smelter starts, it can never stop, so this demand never quits), carbon black (the black powder that makes tyres tough), and a growing basket of fancy speciality chemicals. It is the No. 1 pitch maker in India and one of the five biggest speciality-carbon-black makers on earth. It runs its own plants on power it captures from its own waste gas. That is a real, gritty, useful business with a genuine cost edge.
Here is the remarkable part. Ten years ago this company was nearly dead. In FY15 and FY16 it lost money and groaned under about ₹1,100 cr of debt. Management then did the hard, boring, admirable thing: they paid the debt down, fixed the plants, squeezed out more value per tonne, and turned the ship around. Profit went from a ₹39 cr trickle in FY22 to ₹755 cr in FY26. Today they sit on net cash. That decade is the single best thing on this company’s résumé — it tells you the people running it can both grow and survive.
Now the plot twist. Himadri has spent more than a decade quietly researching the carbon that goes inside lithium batteries. It has now commissioned its first small anode plant, is building a 40,000-tonne LFP cathode plant (with a dream of 200,000 tonnes — “the first outside China”), licensed a silicon-carbon anode technology from Australia’s Sicona, and taken stakes in a US/Korea battery-cell maker (IBC). If even part of this lands, Himadri stops being a steady carbon company and becomes a supplier to the global battery boom. If it stumbles, it will have poured a lot of money into a brutally competitive arena where China makes ~88% of the world’s LFP and keeps cutting prices.
So the tension is simple. The business is good and getting better, and the price is rich and getting richer. You are being asked to pay roughly 45 times earnings — and a steep 7 times book value — for a company whose proven core is worth maybe 25–35 times, with the rest of the price being a down-payment on a battery future that won’t earn real money before FY29. A wonderful boat, but the seat is not cheap. Below are the receipts.
Sitting down with the management
If Buffett and Raamdeo Agrawal sat across from the Choudhary family for an afternoon, I think they would come away impressed — but keeping one hand in their pocket.
The family, led today by Anurag Choudhary (Chairman, Managing Director and CEO, who joined the business at eighteen), has spent three decades mastering one molecule — carbon — and stretching it from coal-tar pitch to carbon black to battery-grade anode. That is the opposite of a financial roll-up; it is a genuine domain obsession, exactly Buffett’s “passion.” The capital-allocation record is where they earn real trust: they took a near-bankrupt, over-leveraged company in FY15–16 and deleveraged it to a net-cash position while still growing — the rarest and most valuable management skill there is. Each retained rupee has plainly created more than a rupee of value; the one-dollar test passes for the last decade with room to spare.
The alignment is excellent. Promoters lifted their stake from about 45% to 52.5% — and crucially they did it by putting fresh cash in (converting warrants at ₹70, ₹237 and ₹316), not by selling. People who buy more of their own stock with their own money, at rising prices, are telling you something. The R&D culture is the soft asset competitors can’t copy: 180-plus scientists, 28 PhDs from around the world, ~₹120 cr a year spent, and — this matters — the anode technology was built in-house, not licensed. Two straight years of EcoVadis Platinum (top 1% globally on environment-and-governance) is a genuine outside validation.
Now the honest concerns. First, the chairman’s letters and concalls read more like a glossy narrative (“Himadri reloaded,” “Together Towards Tomorrow,” “the best chapters are still ahead”) than the plain, mistake-admitting candor Buffett prizes — there is more cheerleading than confession. Second, how they raised their stake deserves scrutiny: warrants issued to promoters at prices that look low against where the stock later traded are perfectly legal, but they are a related-party mechanism, and minority owners should watch them. Third, it is a one-man face: Anurag is the strategist, the spokesman, and the family anchor, and there is no obvious professional CEO-in-waiting — real key-man risk. No SEBI action, auditor qualification, or pledging problem turned up — a clean sheet for the sector.
Would they shake hands? Yes — with one hand in the pocket. The single thing that would change their mind, in either direction, is whether the LFP and anode plants actually earn a clearly positive, sustained return on capital, not merely get commissioned. Until then it is a quality team attached to an unproven bet.
What’s on the horizon (live-issues tracker)
Four live threads will decide the next one-to-three years.
1. The battery-materials bet — the crux (status: 🟡 early, unproven). Full interrogation below.
2. Speciality carbon black ramp-up (🟢 on track). Himadri doubled its speciality carbon black to 130,000 tonnes — now “the world’s single largest single-site speciality carbon black plant.” Management guides 85–90% utilisation of the new line in FY27 at margins above the ₹17,000/tonne basket average. This is the most reliable near-term growth engine: real capacity, real demand, formula-linked pricing that passes input costs to customers. Watch: utilisation hitting the guided 85–90% in FY27 quarters.
3. Coal-tar pitch exports (🟢 early-but-real). New liquid-pitch export terminals at Haldia and Mangalore, distillation de-bottlenecked from 500k to 600k tonnes. Management expects ~50,000 tonnes of pitch exported by FY28 and frames China as no threat (“we supply below Chinese cost”). Watch: export volume actually flowing through the two ports.
4. Birla Tyres revival (🟡 mixed/early). Himadri bought the collapsed Birla Tyres brand out of insolvency and is rebuilding it. FY26 revenue was just ₹187 cr; management dreams of ₹3,000 cr in four years. It is early, the tyre market is crowded, and a planned passenger/EV radial plant is 24 months out. Watch: whether the ₹187 cr base actually scales and turns a profit, or quietly stalls.
The crux — the battery-materials bet, interrogated
The crux in one sentence: This investment justifies its rich price if and only if Himadri’s LFP cathode and anode capacity earns a genuinely high, sustained return on capital against entrenched Chinese competition — not merely gets built.
The mechanism, in plain terms. A lithium battery cell is mostly two powders: the cathode (here, lithium-iron-phosphate, “LFP”) and the anode (graphite/carbon, increasingly with a dash of silicon). Together they are ~65% of a cell’s cost. Himadri’s bet is that the carbon mastery it already has — especially its in-house high-purity coal-tar pitch, which is the raw material for anode — gives it a backward-integrated cost and quality edge no one else outside China owns. The honest test of the analogy: is this like Himadri’s existing pitch business, where being the low-cost, backward-integrated maker built a durable moat? Partly. The manufacturing skill transfers. But the competitive arena does not — pitch competes against a sleepy, fragmented field, while LFP competes against the most aggressive, scaled, price-cutting industry on the planet.
The competition, by name:
| Threat | Who / backed by | Position | Proof point |
|---|---|---|---|
| Chinese LFP majors | Hunan Yuneng, Dynanonic, others | ~88% of global LFP cathode | Mature cost curves; LFP-material prices fell ~75% in ~3 years (HSCL’s own number) |
| Indian battery-materials entrants | Various (Epsilon Advanced, Altmin, others) | Sub-scale, racing | None at HSCL’s planned scale yet |
| HSCL itself | promoter cash + in-house tech | First non-China LFP at scale (claimed) | Anode plant commissioned 23-Apr-2026; LFP demo by Q3 FY27 (HARD/MEDIUM) |
The precedent. China’s own LFP industry shows the shape of the prize and the danger: 15+ years of quiet research, then a 4-year demand explosion, then a brutal 75% price collapse as capacity flooded in. Anyone arriving late to a commodity-chemistry race tends to meet falling prices. Himadri’s counter is that it arrives with backward integration and “demand will not be the constraint” (global cell capacity heading from ~2,500 to ~8,000 GWh) — i.e., it is selling into a flood of new demand, not fighting over a fixed pie. That is the bull’s strongest card, and it is a real one.
The follow-on questions, answered.
- Is the risk to volume or to price? Price. Management itself says lithium pricing is a full pass-through and material prices already fell 75%. So Himadri’s risk is margin-per-tonne in a commoditising product, not finding buyers.
- Which part is protected? The core carbon business (pitch, carbon black) is insulated and keeps earning — the battery bet is incremental, funded from internal accruals, with no plan to take on heavy debt or dilute.
- Has anyone actually bought yet? Not at scale. Samples are out to “who’s who” global and Indian cell makers; offtake agreements exist under NDA but are undisclosed and unproven. This is the single biggest “show me.”
- Is the bet with or against the current? With the demand current (battery growth is structural), but against the cost current (China’s scale).
Honest view: not “too hard,” but “not yet earned.” The core business is a clear, knowable Good-bordering-Great compounder. The battery bet is a genuine, well-funded, disciplined option built on real R&D — but it is optionality, not value, until a plant runs full and earns its guided 30%-plus return on capital. The price today already pays for a fair bit of that option. The patient reader’s job is to watch the proof points, not the press releases.
The watch-list (checkable next 1–4 quarters):
- Speciality carbon black utilisation reaching 85–90% in FY27.
- The LFP demo plant (2,000 t) commissioning by Q3 FY27 — on time, not slipping.
- Any disclosed, binding LFP/anode offtake (today all NDA).
- Coal-tar pitch export tonnage building through Haldia + Mangalore.
- Birla Tyres moving past ₹187 cr toward profitability — or stalling.
- RoCE staying above ~22% as battery capital is deployed (the early warning that the bet is diluting returns).
QGLP scorecard (the Motilal Oswal lens) — the receipts
Business-quality score = Quality + Growth + Longevity = 17.5 / 23. Price (Q24–25) is reported separately below.
| # | Question | Score | Evidence |
|---|---|---|---|
| Quality of Business | 5/6 | ||
| 1 | Large opportunity? | 1 | Carbon/coal-tar + battery materials — vast, multi-decade TAM (about) |
| 2 | Favourable industry structure? | 1 | No.1 pitch, top-5 carbon black; rising, stable OPM 9%→21% (profit_loss) |
| 3 | Defensible moat? | 1 | Backward integration, in-house tech, cost edge; RoCE >15% in 5 of last 6 yrs (ratios_table) |
| 4 | High return ratios (>15%)? | 0.5 | RoE 17.8%, RoCE 22.1% now — but only recently durable; was 4–5% in FY21 (ratios) |
| 5 | Asset-light? | 0.5 | Capital-hungry (CWIP ₹372 cr, big capex) but earns well — a “Good” company, not a See’s |
| 6 | Favourable terms of trade? | 1 | ToT ~117% but cash-conversion cycle ~103d, manageable; banks customers lightly (ratios_table) |
| Quality of Management | 4/6 | ||
| 7 | Unquestionable integrity? | 0.5 | Clean (no SEBI/auditor flags) but promoter warrant-led stake build at low prices a watch-item |
| 8 | Proven execution? | 1 | Decade turnaround FY15 loss → ₹755 cr PAT; beat its own PAT-doubling guidance early |
| 9 | Growth mindset & vision? | 1 | Decade of quiet battery R&D, ₹120 cr/yr spend, in-house anode tech |
| 10 | Superior capital allocation? | 1 | Deleveraged, net cash, reinvests at high RoCE, no value-destroying M&A yet (one-dollar test passes) |
| 11 | Clear succession plan? | 0 | Heavy reliance on Anurag Choudhary; no visible professional CEO bench |
| 12 | Minority interests protected? | 0.5 | Promoters add cash (good); warrants priced friendly (watch); thin 5% payout |
| Growth | 5/6 | ||
| 13 | Structural tailwind? | 1 | Aluminium, tyres, EV batteries, import substitution — all >GDP |
| 14 | Volume-led vs price? | 0.5 | Recent growth value-mix-led (volume +3%, EBITDA/t +15%); top line flat 2 yrs |
| 15 | Operating leverage? | 1 | OPM 6% (FY22) → 21% (FY26) as sales grew (profit_loss) |
| 16 | Manageable leverage? | 1 | Net cash ₹121 cr; debt-to-equity low; growth from accruals (concall) |
| 17 | Market-share gain potential? | 0.5 | Gaining in carbon black/exports; battery share unproven |
| 18 | Earnings growth >15% CAGR? | 1 | PAT 5-yr CAGR ~74%, 3-yr ~52% (profit_loss); guided ~26% to FY28 |
| Longevity | 3.5/5 | ||
| 19 | Relevant 10–15 yrs (low disruption)? | 1 | Pitch demand is inelastic (smelters can’t stop); carbon is forever |
| 20 | Can extend CAP (moat)? | 0.5 | Core moat widening; battery moat unproven against China |
| 21 | Can sustain GAP (runway)? | 1 | Long runway — exports + batteries + import substitution |
| 22 | Geographic / product headroom? | 0.5 | 61 export countries, new products — but battery is the swing factor |
| 23 | Adaptive, resilient culture? | 0.5 | Survived FY15–16 near-death; strong R&D DNA; not battle-tested in batteries |
| Business total | 17.5 / 23 | ||
| Price (Q24–25, shown separately) | 0.5 / 2 | PEG ~1.7×, payback ~4.3× — see price section | |
| (Canonical QGLP /25 for fidelity) | 18.0 / 25 |
The pattern: Quality and Growth are the strength — a real moat on the core, RoE/RoCE comfortably above the cost of money, and explosive recent earnings. The two soft spots are succession (one-man dependence) and Longevity’s battery question. Price is the only thing standing between this and a clean buy-zone — and right now it stands tall.
Buffett lens (the Berkshire-letters read)
| # | Test | Result | Evidence |
|---|---|---|---|
| 1 | Good boat? (business > management) | PARTIAL | A Good, capital-hungry business that earns well — not a fountain-of-cash Great |
| 2 | Moat + franchise + pricing power | PASS | Stable/rising OPM through cost spikes (full pass-through); No.1 pitch; cost edge |
| 3 | See’s test (high returns, little capital) | PARTIAL | High RoCE but needs heavy capex; FCF lumpy/negative in growth years (cash_flow) |
| 4 | Capital allocation (one-dollar test) | PASS | Deleveraged near-bankrupt B/S to net cash; retained rupees compounded value |
| 5 | Owner-oriented, candid management | PARTIAL | Promoters add cash; but letters are glossy/narrative, warrants promoter-friendly |
| 6 | Integrity / forensic (no “credit P&L, debit B/S”) | PASS | OCF broadly tracks PAT over time (CFO/OP ~64–77% recent); no balance-sheet bloat flags |
| 7 | Circle of competence / predictability | PARTIAL | Core is predictable; battery future is genuinely hard to forecast |
| 8 | Mr. Market — gift or trap now? | FAIL | P/E 45, P/B 7.2× with euphoric battery narrative — priced for perfection |
| 9 | Patience / compounding runway | PASS | Long runway (exports, batteries, import substitution) at high RoCE |
| 10 | The honest red flag | (see below) | Paying ~45× for a capital-hungry commodity-chemistry bet vs entrenched China |
Score: 6.5 / 10 PASS — a real business with real gaps; not in the temple at this price, but close on quality.
The See’s test, spelled out. See’s Candies was Buffett’s dream: it threw off cash and barely needed reinvestment. Himadri is the opposite shape. It earns a fine 22% on capital, but to grow it must keep building plants — capex has been heavy (CWIP up to ₹372 cr, investing cash-out ₹963 cr in FY26), and free cash flow swings negative in build years. That is the textbook “Good” company: profitable, but it must keep feeding the machine to grow. Not a sin — just not a See’s.
The one-dollar test, spelled out. Has each retained rupee created at least a rupee of market value? Emphatically yes over the decade. Net worth grew from ~₹790 cr (FY15) to ~₹4,706 cr (FY26) while the company went from losses to ₹755 cr profit, and the market now values it at ₹33,857 cr. Retained earnings have compounded book value, earnings, and market value — the cleanest pass in this whole report. The open question is purely forward: will the rupees about to go into batteries clear the same bar?
The framework metrics
- Economic Profit = ₹4,706 cr net worth × (RoE 17.8% − CoE 12%) = +₹273 cr — creating real value above the cost of owners’ money. (CoE = 12%, the middle of the studies’ 10–15% range.)
- Terms of Trade = Debtor days 55 / Payable days 47 ≈ 117% — slightly unfavourable (it funds its customers a little); cash-conversion cycle ~103 days, and working-capital days have crept up (32→69→57). Not an FMCG cash machine.
- 5-yr Payback = Mcap ₹33,857 cr / projected cumulative 5-yr PAT ≈ 4.3× (assuming ~26% PAT CAGR, management’s own guided pace). Well above the <1× multi-bagger signal — the price has run ahead of the earnings.
- PEG = P/E 45.2 / ~26% guided growth = ~1.7× (or ~0.9× if you use the unrepeatable ~52% recent burst — but that base-effect growth won’t persist). Above the 1× discipline line.
- RoE − CoE spread = +5.8%; RoE has been above 15% in only about 3 of the last 10 years — the high returns are recent, not a decade-long franchise yet.
- Consistent vs Volatile test = historically Volatile (losses in FY15–16; PAT cratered FY21–22 in the cycle), but the last four years are a clean, rising series. It is transitioning from Volatile to Consistent — value it cautiously on earnings, with respect for the cyclicality in its DNA.
Peer comparison
| Company | Mkt cap | CMP | P/E | P/B | RoE | RoCE | OPM | Latest sales |
|---|---|---|---|---|---|---|---|---|
| Himadri (HSCL) | ₹33,857 cr | ₹671 | 45.2 | 7.2× | 17.8% | 22.1% | 21% | ₹4,661 cr |
| PCBL Chemical | ₹12,178 cr | ₹310 | 56.7 | 3.0× | 5.6% | 7.8% | 13% | ₹8,189 cr |
| Atul Ltd | ₹19,084 cr | ₹6,482 | 28.2 | 3.1× | 11.5% | 14.9% | — | — |
| Epigral | ₹4,865 cr | ₹1,128 | 14.8 | 2.2× | 16.0% | 15.5% | — | — |
Source: each peer’s screener snapshot, 2026-06-20.
The peer read is double-edged. On business quality, Himadri is clearly the best of this set right now — its RoE (17.8%) and RoCE (22.1%) tower over PCBL (the closest carbon-black peer, whose FY26 profit just collapsed to ₹198 cr from ₹435 cr, compressing margins and spiking its P/E), and beat Atul too. Himadri is the strongest operator in its asset class. On price, though, it is the most expensive on both P/E and — strikingly — P/B (7.2× vs 2–3× for everyone else). So the relative read agrees with the absolute one here: Himadri is the quality leader, but you pay a fat premium for it, and the premium is largely the battery story. Epigral, for contrast, offers similar return ratios at a third of the multiple — a reminder of what “cheap quality” looks like in this sector.
Latest quarter & what’s happening now
Q4 FY26 (reported 27 April 2026): consolidated revenue ₹1,288 cr (+14% YoY), EBITDA ₹280 cr (+21%), PAT ₹208 cr (+34%) — the strongest quarter ever. Full-year FY26: revenue ₹4,661 cr, EBITDA ₹1,006 cr, PAT ₹755 cr (+36%), RoCE ~32% (management’s number), net cash ₹121 cr.
Two concall takeaways. (1) Management beat its own guidance. A year ago it promised to double FY25 PAT (₹555 cr) by FY28; it has nearly done it already and re-set the same “double again by FY28” target — and noted “last time it took 2 years instead of 3.” That is delivery, not just talk. (2) The capex is disciplined and demand-led. Anurag is explicit: “we don’t allocate capital to any business where RoCE is less than 30%,” and the LFP plant is being built in 2,000-tonne then 38,000-tonne steps to avoid deploying cash ahead of approvals. That ROCE-first discipline is the best protection against the battery bet becoming a money pit. Live catalysts: anode plant commissioned (HARD, Apr-2026); LFP demo by Q3 FY27 (MEDIUM); anthraquinone/carbazole import-substitution plant by Q2 FY27 (MEDIUM); FY27 flagged as the first real top-line and bottom-line growth year (MEDIUM).
Where the two lenses agree — and disagree
They agree on the business: a Good, moaty, well-run compounder that has earned its turnaround and creates positive economic profit. QGLP’s 17.5/23 and Buffett’s 6.5/10 both say “real quality, a couple of gaps.”
They disagree most sharply on two things. First, price: QGLP’s checklist would almost wave it through on growth and quality, but Buffett’s Mr.-Market test (#8) flatly fails it at 45× earnings and 7× book — the letters weight price discipline harder than a quality checklist does, and that is the divergence that matters most today. Second, predictability (Buffett #7): the checklist happily scores the battery growth, but the circle-of-competence test only goes PARTIAL because the battery future is genuinely hard to forecast. Trust the Buffett flags here — they are catching what the scorecard’s optimism papers over: a wonderful enough business at an unwonderful price, with its biggest growth driver still a question mark.
The price as a current phenomenon
This section judges the price, not the business — the business verdict above is already settled.
The margin-of-safety band. QGLP’s price discipline wants PEG ≤ 1× and/or 5-yr payback ≤ 1×. Himadri clears neither today (PEG ~1.7×, payback ~4.3×). Working backwards: a PEG near 1× on management’s ~26% guided growth implies a P/E around 26×, and a P/E in the high-20s-to-mid-30s on FY26 EPS of ₹14.89 implies a band of roughly ₹390–₹520. That is the price at which the framework’s arithmetic starts to feel like value rather than faith. The current ₹671 sits about 30–70% above it.
Mr. Market’s mood: greedy, and you can see why. The crowd is excited — and not irrationally — about “the only commercial LFP maker outside China,” a real battery-materials build, promoters buying more stock, and a record-profit core. That excitement is doing the heavy lifting in the 45× multiple and the eye-watering 7× book value. The danger is that battery sentiment is fickle: lithium prices have already fallen 75%, Chinese oversupply is the headline risk, and any slip in the LFP timeline could de-rate the multiple hard — without a single thing changing in the carbon business that actually makes the money today.
The tension, stated plainly: this is the classic case of a wonderful enough business at an unwonderful price. A patient owner who admires the boat must decide whether to wait for calmer pricing or pay up for the option. Not a recommendation — and remember, this reading can flip next week while everything in the boxes above stays exactly the same.
Conviction texture
The bull case, at its strongest: A management team that resurrected a dying company now runs it net-cash with 22%+ RoCE, rising margins, a real cost moat in carbon, and a decade-quiet, fully in-house battery-materials program arriving just as global cell capacity triples — selling into demand that “won’t be a constraint,” with promoters putting their own cash in at every step. If even a third of the LFP/anode ambition lands at the guided 30%+ RoCE, today’s price will look cheap in hindsight.
The bear case, at its strongest: You are paying 45× earnings and 7× book — the dearest in its peer set on both — for a capital-hungry company whose core grows in single-to-mid-digits on volume, and whose entire premium rests on a commodity-chemistry battery bet against an 88%-share Chinese industry that just cut prices 75%. The high returns are only ~3 years old in a business that lost money a decade ago; working capital is creeping up; the chairman talks in glossy slogans; succession rests on one man; and promoters lifted their stake via friendly-priced warrants. If the battery story slips, the multiple — not the business — is what gets hurt.
What the numbers actually support: a genuinely Good, improving business creating positive economic profit, run by a proven-but-promotional team, priced today for a battery future it has not yet earned. The quality is real; the price is the risk. Watch the six items on the watch-list — especially RoCE staying above ~22% as battery capital goes in, and any disclosed, binding offtake — and let the proof points, not the narrative, move your conviction. No buy/sell/hold.
Sources
- Screener snapshot: https://www.screener.in/company/HSCL/consolidated/ (fetched 2026-06-20)
- HSCL Q4 & FY26 earnings concall, 27 April 2026 (transcript filed 02-May-2026)
- HSCL Q3 & 9M FY26 earnings concall, 21 January 2026 (transcript filed 28-Jan-2026)
- HSCL Annual Report FY25 & FY26 (chairman/governance/risk/segment sections)
- Peer snapshots (screener, 2026-06-20): PCBL Chemical, Atul Ltd, Epigral
- Management/promoter web research: company filings, Business Standard, Indian Chemical News, EcoVadis/PRNewswire, exchange filings on warrant conversions, analyst notes (dated/tagged HARD/MEDIUM/SOFT inline)
- Assumptions: Cost of Equity 12%; forward PAT growth ~26% (management’s FY25→FY28 PAT-doubling guidance); FY26 EPS ₹14.89; CMP ₹671.